Cargando…

Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability

BACKGROUND: Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. OBJECTIVE: To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sotiropoulos, Marinos G, Lokhande, Hrishikesh, Healy, Brian C, Polgar-Turcsanyi, Mariann, Glanz, Bonnie I, Bakshi, Rohit, Weiner, Howard L, Chitnis, Tanuja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165535/ https://www.ncbi.nlm.nih.gov/pubmed/34104471 http://dx.doi.org/10.1177/20552173211015503

Ejemplares similares

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Author Correction: Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study
por: Zhao, Yijun, et al.
Publicado: (2020)

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases
por: Saxena, Shrishti, et al.
Publicado: (2020)

History of fatigue in multiple sclerosis is associated with grey matter atrophy
por: Palotai, Miklos, et al.
Publicado: (2019)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

Risk attitudes and risk perceptions in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2016)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course
por: Bove, Riley, et al.
Publicado: (2013)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
por: Rosso, Mattia, et al.
Publicado: (2020)

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis
por: Yousuf, Fawad, et al.
Publicado: (2016)

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients
por: Rosso, Mattia, et al.
Publicado: (2019)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
por: Bove, Riley, et al.
Publicado: (2013)

Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets
por: Guo, Michael H., et al.
Publicado: (2022)

Increased leptin and A-FABP levels in relapsing and progressive forms of MS
por: Messina, Silvia, et al.
Publicado: (2013)

Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity
por: Zhang, Tingting, et al.
Publicado: (2020)

A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis
por: Xia, Zongqi, et al.
Publicado: (2010)

Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2019)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
por: Chu, Renxin, et al.
Publicado: (2016)

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis
por: Chitnis, Tanuja
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_g97vofrkbj04ipib3jarttcstb